Arrivobio
Founded 2015 · 15 employees on LinkedIn · 3 known investors
Find your way into Arrivobio
Arrivo Bio develops novel, disease-modifying medicines targeting the root cause of hard-to-treat diseases for which few effective treatment options exist. The company partners with Mayo Clinic and Daiichi Sankyo to advance first-of-its-kind therapies.
Investors · 3
Frequently asked questions
- What does Arrivobio do?
- Arrivo Bio develops novel, disease-modifying medicines targeting the root cause of hard-to-treat diseases for which few effective treatment options exist. The company partners with Mayo Clinic and Daiichi Sankyo to advance first-of-its-kind therapies.
- Who are Arrivobio's investors?
- Arrivobio's investors include Orlando Health Ventures, Rex Health Ventures, Solas BioVentures.